Kidney Health Initiative Urges Investigators to Include People with Kidney Diseases in Clinical Trials for Coronavirus 2019 (COVID-19) Therapies

American Society of Nephrology (ASN)

 

Highlights:

  • People with kidney diseases are often excluded from clinical trials because of the complexity and high morbidity of kidney disease.
  • COVID-19 puts people with kidney diseases at a two to sixteen-fold increased risk of severe symptoms.
  • All investigators should include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19.

  

Newswise — Washington, DC (June 9, 2020) — Clinical trials often exclude people with kidney diseases. This practice could have significant consequences, if continued, during the Coronavirus – 2019 (COVID-19) pandemic and for the 37 million Americans with kidney diseases who are at high risk of severe disease.

Preliminary studies indicate that people with kidney diseases demonstrate an increased risk (two- to sixteen-fold) for developing severe COVID-19 symptoms. These data support US statistics that show acute kidney injury occurs in up to 5% of hospitalized COVID-19 patients and 50-90% of patients in the intensive care unit. An effective response to the COVID-19 pandemic should include people with kidney diseases.

The KHI Board of Directors considered a variety of issues impacting drug and device development in the kidney community during the COVID-19 pandemic and identified inclusion of people with kidney diseases in clinical trials for COVID-19 therapies as central to improving care. The recent statement, written by members of the Board of Directors is titled “Making the Case for Change: Including People with Kidney Diseases in COVID-19 Trials”.

“Given their increased risk, people with kidney diseases deserve to be prioritized in the development of novel therapies for COVID-19,” said Raymond C. Harris, MD, FASN, Co-Chair of KHI, “KHI urges sponsors and investigators to come alongside the US Food and Drug Administration (FDA) and the patient community to expand their research into this vulnerable population.”

The FDA encourages enrollment practices that lead to clinical trials better reflecting the population most likely to use and benefit from the therapy being studied. This can be achieved through novel trial designs or broadening eligibility criteria, when appropriate, to increase enrollment of underrepresented populations. A recent guidance from the FDA titled “COVID-19: Developing Drugs and Biological Products for Treatment or Prevention” explicitly encouraged sponsors to include people with kidney diseases in their COVID-19 trials.   

As the largest consortia in the kidney community and a public-private partnership between the American Society of Nephrology and the FDA, KHI urges all investigators to include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19. This population demonstrates increased risk of exposure, infection, and severe morbidity, and inclusion of people with kidney diseases in trials would benefit all aspects of health care.

Individuals who are interested in learning more about KHI, should contact Melissa West, Acting Vice President for Research, Discovery and Innovation, at [email protected]

The Kidney Health Initiative (KHI) is a key part of the newly created ASN Alliance for Kidney Health. KHI is uniquely positioned to realize ASN’s vision of a world without kidney diseases. As a public-private and collaborative partnership with the FDA and more than 100 organizations and companies, KHI catalyzes innovation and the development of safe and effective patient-centered therapies for people living with kidney diseases. Learn more at www.kidneyhealthinitiative.org.

 

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.

 

# # #

 

 




Filters close

Showing results

110 of 5382
access_time Embargo lifts in 2 days
Embargo will expire: 14-Apr-2021 2:00 PM EDT Released to reporters: 12-Apr-2021 4:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 14-Apr-2021 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Texas A&M researchers leaders in study of COVID-19 blocking enzyme
Released: 12-Apr-2021 4:05 PM EDT
Texas A&M researchers leaders in study of COVID-19 blocking enzyme
Texas A&M AgriLife

Collaborative study shows K777 effective in combatting SARS-CoV-2 virus

Released: 12-Apr-2021 3:05 PM EDT
Scientists Reveal COVID-19 News, Next Frontier in Fighting Substance Abuse, More
Federation of American Societies for Experimental Biology (FASEB)

Register for online access to cutting-edge science at Experimental Biology 2021, April 27–30

Released: 12-Apr-2021 3:05 PM EDT
Double-Lung Transplant After COVID-19 Performed in Canada
University Health Network (UHN)

Case done at University Health Network is believed to be a first in Canada on a patient whose lungs were irreparably damaged by COVID-19

Newswise: How Cedars-Sinai Prepared for Pandemic Patients
Released: 12-Apr-2021 1:05 PM EDT
How Cedars-Sinai Prepared for Pandemic Patients
Cedars-Sinai

When the COVID-19 pandemic hit, healthcare professionals around the globe had to quickly learn to stay safe

Newswise: Workplace Communication Study During Pandemic Finds Managers Should Talk Less, Listen More
Released: 12-Apr-2021 11:05 AM EDT
Workplace Communication Study During Pandemic Finds Managers Should Talk Less, Listen More
Baylor University

Managers should listen more, be empathetic and be sure they give feedback — even if they cannot solve a problem immediately, according to a Baylor University study that focused on workplace communication during the pandemic. The crisis highlighted the need for better on-the-job communication with employees now and in the future, when the pandemic recedes, researchers said.

Released: 12-Apr-2021 9:00 AM EDT
Pandemic Paradox: People Want to Improve Mental Health by Exercising, but Stress and Anxiety Get in the Way, Research Shows
McMaster University

The pandemic has created a paradox where mental health has become both a motivator for and a barrier to physical activity.

Newswise: NIEHS earns WELL building rating amid pandemic
Released: 12-Apr-2021 9:00 AM EDT
NIEHS earns WELL building rating amid pandemic
National Institute of Environmental Health Sciences (NIEHS)

On March 30, 2021, the National Institute of Environmental Health Sciences (NIEHS) became the first federal agency to achieve the International WELL Building Institute’s Health-Safety Rating.

access_time Embargo lifts in 2 days
Embargo will expire: 15-Apr-2021 4:00 PM EDT Released to reporters: 12-Apr-2021 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 15-Apr-2021 4:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 12-Apr-2021 9:00 AM EDT
Large US study suggests survival benefit for severely ill COVID-19 patients treated with ECMO
Wolters Kluwer Health: Lippincott

For critically ill COVID-19 patients treated with extracorporeal membrane oxygenation (ECMO), the risk of death remains high – but is much lower than suggested by initial studies.


Showing results

110 of 5382

close
2.08426